Last reviewed · How we verify
NCT06821633
Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients
NA trial testing Targeted laser photocoagulation guided by OCTA (Optical Coherence Tomography Angiography) in Diabetic Retinopathy in 30 participants. Not yet recruiting.
7 August 2026
Quick facts
| Lead sponsor | Sichuan Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 7 July 2025 |
| Primary completion | 7 August 2026 |
| Estimated completion | 7 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Targeted laser photocoagulation guided by OCTA (Optical Coherence Tomography Angiography)
Conditions studied
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Sponsor
Sichuan Provincial People's Hospital
Who can join
18 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the impact of widefield OCTA-guided selective photocoagulation on the progression of diabetic retinopathy (DR) by comparing the control of non-perfusion (NP) areas, DR grading, and management of other DR lesions. The study is designed as a parallel randomized controlled trial. From February 2025 to August 2026, 30 diabetic patients attending the Ophthalmology Department of Sichuan Provincial People's Hospital will be enrolled. Using a simple randomization method, one eye of each patient will be assigned to the intervention group, while the contralateral eye will serve as the control, resulting in 30 eyes in each group. The intervention group will undergo OCTA-guided selective photocoagulation, specifically using a grid pattern (3x3) of spot laser applied once to the NP area, extending one spot diameter beyond the NP boundary. Each session will last 10-20 minutes. The control group will receive no treatment. The study will compare changes in NP area, DR grading progression, and control of other DR lesions at 3, 6, 9, and 12 months between the two groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06821633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Retinopathy
Currently open trials in the same condition.
- NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
- NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting
Other Sichuan Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07298525 — Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monito · Phase 4 · not yet recruiting
- NCT07175363 — Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study · not yet recruiting
- NCT07106996 — Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycysti · EARLY_PHASE1 · recruiting
- NCT07082946 — Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients · not yet recruiting
- NCT07012434 — Exploring the Mechanisms of Postoperative Delirium in Cirrhotic Patients Through Multi-Omics Integrative Analysis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06821633 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Provincial People's Hospital
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06821633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing